18F-fluoroestradiol (18F-FES) is a Food and Drug Administration-approved radiopharmaceutical used for molecular imaging of the estrogen receptor (ER). When combined with PET, 18F-FES may improve the diagnosis of ER-positive breast cancer in the metastatic setting and provide insights into tumor heterogeneity. In this article, we review data on the use of 18F-FES imaging for treatment selection, staging, imaging lobular breast cancer, and the novel breast specific imaging tool, dedicated breast PET
developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-F...
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivit...
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, t...
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortalit...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PS...
For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major rol...
Molecular imaging of breast cancer can potentially be used for breast cancer screening, staging, res...
Abstract Background Breast cancer heterogeneity reflects the complex biology of this disease. Breast...
Oestrogen receptors are overexpressed in around 70% of all breast cancers, and are a target for endo...
PURPOSE: The aim of the study was to determine the correlation between 16\u3b1-18F-fluoro- 17\u3b2-...
developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-F...
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivit...
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, t...
Breast cancer is one of the most commonly diagnosed cancers and the leading cause of cancer mortalit...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
16 alpha-F-18-fluoro-17 beta-estradiol (F-18-FES) is an estrogen receptor (ER)-specific PET tracer w...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individ...
Recent advances with specific PET tracer ligands, for example prostate-specific membrane antigen (PS...
For patients with estrogen receptor (ER) positive breast cancer, endocrine therapy plays a major rol...
Molecular imaging of breast cancer can potentially be used for breast cancer screening, staging, res...
Abstract Background Breast cancer heterogeneity reflects the complex biology of this disease. Breast...
Oestrogen receptors are overexpressed in around 70% of all breast cancers, and are a target for endo...
PURPOSE: The aim of the study was to determine the correlation between 16\u3b1-18F-fluoro- 17\u3b2-...
developed and tested as an agent for the imaging of estrogen receptor (ER) expression in vivo. 18F-F...
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivit...
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, t...